Please assess the completion status of the following clinical trial:

Trial Title: Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to adhere to medication regimen~* Speaks English~* Assigned female at birth with intact ovaries~* Premenopausal~* Normal menstrual cycles between 25-35 days~* Under current care of an outpatient mental health provider with visits occurring at least once every 3 months.~* At least 1 year postpartum.~* Willing to use a barrier method of birth control during the study.~* Normal weight (BMI between 18-29)~* Must report at least some recent suicidal ideation (in the past month) at the time of recruitment.~* Must be categorized as having acceptably low imminent risk for suicidal crisis/attempt by a licensed clinical psychologist utilizing evidence-based clinical and research guidelines for imminent suicide risk management.~Exclusion Criteria:~* Must not be pregnant, breastfeeding, or trying to become pregnant.~* Must not be taking any form of exogenous hormones or hormonal intrauterine device, and must have ended previous use of hormonal preparations at least one month prior to the study.~* Must not have a personal history of any chronic medical condition, including but not limited to metabolic or autoimmune disease, epilepsy, endometriosis, cancer, diabetes, cardiovascular, gastrointestinal, hepatic, renal, or pulmonary disease, and no personal or first degree family history of thromboembolic events.~* Any current cigarette smoking is exclusionary.~* Must not report a history of clinical diagnosis or treatment for postpartum depression or premenstrual dysphoric disorder (Note: Premenstrual Dysphoric Disorder diagnosis must have been made based on prospective daily ratings).~* Must not report any history of manic episode, any history of psychotic symptoms, or current substance use disorder.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Active condition, then Inactive condition (Type: EXPERIMENTAL): Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
- Inactive condition, then active condition (Type: PLACEBO_COMPARATOR): Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).